182P - A prospective, molecular epidemiological study of EGFR mutations in Asian patients (pts) with advanced non-small-cell lung cancer with adenocarcinom...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Biomarkers
Non-Small-Cell Lung Cancer, Metastatic
Presenter Yuan-Kai Shi
Authors Y. Shi1, S. Zhang2, M. Wang3, S. Yang4, N. Li5, G. Wu6, W. Liu7, G. Liao8, K. Cai9, L. Chen10
  • 1Medical Oncology Department, Cancer Institute & Hospitall, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 2Department Of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing/CN
  • 3Department Of Respiratory Medicine, Peking Union Medical College Hospital, Beijing/CN
  • 4Department Of Medical Oncology, Henan Cancer Hospital, Zhengzhou/CN
  • 5Department Of Medical Oncology, Guangzhou Chest Hospital, Guangzhou/CN
  • 6Cancer Centre Of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei/CN
  • 7Department Of Medical Oncology, Fourth Hospital, Hebei Medical University, HEBEI/CN
  • 8Department Of Medical Oncology, 309 Hospital, Beijing/CN
  • 9Department Of Medical Oncology, South Hospital, Guangzhou/CN
  • 10Department Of Medical Oncology, 301Hospital, Beijing/CN



The presence of EGFR mutations has been demonstrated to be associated with sensitivity to EGFR-TKIs by several phase III studies, but there's limited information of prospective EGFR mutation data in real-life setting in Asian population. The epidemiological prospective study (NCT01185314; PIONEER) investigated EGFR mutation (M) frequency in pts from Asia with newly diagnosed advanced lung adenocarcinoma (ADC) and the influence of demographic and clinical factors on EGFR M frequency. Here we report analysis results for the subset of pts from China.


Pts were aged ≥20 years, with treatment naïve stage IIIB/IV lung ADC. Tumor sample (biopsy, surgical specimen, cytology) EGFR M status (primary endpoint; positive [M + ], negative [M-], undetermined [MU]) was determined using the Therascreen EGFR RGQ kit. EGFR M frequency was calculated and compared between demographic/clinical factor subgroups.


Of 747 pts in China (50.4% of the overall study population), 46.9% were female, mean age was 57 years (range 17-83), and 56% were never-smokers. EGFR M status was evaluated in 741 patients (6 [0.8%] were MU): 372 (50.2%) were M + , 369 (49.8%) were M-. Gender, smoking status, pack years, metastasis, (all p < 0.001) and disease stage (p = 0.002) were significantly associated with presence of EGFR M. EGFR M+ frequency was 60.6% in females, 41.0% in males, 59.6% in never smokers, and 35.3% in regular smokers. When combine gender and smoking status on overall judgment, the EGFR M+ frequency was 52.7% in male non-smokers, 61.5% in female non-smokers, 35.8% in male regular smokers, and 27.3% in female regular smokers.

Summary of individual mutation types
Number (%) of pts
Number of patients with EGFR mutation test success 741 (100.0)
Exon 18
G719X 4 (0.5)
Exon 19
Deletion 182 (24.6)
Exon 20
T790M 3 (0.4)
S768I 8 (1.1)
Insertion 15 (2.0)
Exon 21
L858R 169 (22.8)
L861Q 6 (0.8)


The overall EGFR mutation frequency in clinically unselected ADC was 50.2%. Smoking status and pack years had a statistically significant association with presence of EGFR mutation, but even in regular smokers, the mutation frequency was 35.3%.


All authors have declared no conflicts of interest.